CL2017001135A1 - Anticuerpos mejorados contra il-6 - Google Patents

Anticuerpos mejorados contra il-6

Info

Publication number
CL2017001135A1
CL2017001135A1 CL2017001135A CL2017001135A CL2017001135A1 CL 2017001135 A1 CL2017001135 A1 CL 2017001135A1 CL 2017001135 A CL2017001135 A CL 2017001135A CL 2017001135 A CL2017001135 A CL 2017001135A CL 2017001135 A1 CL2017001135 A1 CL 2017001135A1
Authority
CL
Chile
Prior art keywords
antibodies against
enhanced antibodies
enhanced
diseases
antibodies
Prior art date
Application number
CL2017001135A
Other languages
English (en)
Inventor
Michael March Schmidt
Alison Tisdale
Eric Steven Furfine
Papastoitsis Grigorios Zarbis
Original Assignee
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc
Publication of CL2017001135A1 publication Critical patent/CL2017001135A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invencion se relaciona con anticuerpos mejorados contra IL-6 que modulan su actividad y los usos de estos anticuerpos en el tratamiento de enfermedades, mas expecíficamente de enfermedades oculares.</p>
CL2017001135A 2014-11-07 2017-05-05 Anticuerpos mejorados contra il-6 CL2017001135A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
CL2017001135A1 true CL2017001135A1 (es) 2017-12-15

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001135A CL2017001135A1 (es) 2014-11-07 2017-05-05 Anticuerpos mejorados contra il-6

Country Status (33)

Country Link
US (2) US11142571B2 (es)
EP (3) EP3215530B9 (es)
JP (1) JP6594438B2 (es)
KR (2) KR20240023450A (es)
CN (1) CN107249631B (es)
AU (1) AU2015342882B2 (es)
BR (1) BR112017008672A2 (es)
CA (1) CA2965689C (es)
CL (1) CL2017001135A1 (es)
CO (1) CO2017005404A2 (es)
CR (1) CR20170231A (es)
DK (1) DK3215530T3 (es)
EA (1) EA035199B1 (es)
ES (1) ES2756275T3 (es)
HK (1) HK1244008A1 (es)
HR (1) HRP20191945T1 (es)
HU (1) HUE046181T2 (es)
IL (1) IL251858B (es)
MA (1) MA51554A (es)
MX (2) MX2017005992A (es)
MY (1) MY185114A (es)
NZ (1) NZ731090A (es)
PE (1) PE20171107A1 (es)
PH (1) PH12017500809A1 (es)
PL (1) PL3215530T3 (es)
PT (1) PT3215530T (es)
RS (1) RS59805B1 (es)
SA (1) SA517381458B1 (es)
SG (2) SG11201703574VA (es)
SI (1) SI3215530T1 (es)
UA (1) UA122673C2 (es)
WO (1) WO2016073890A1 (es)
ZA (1) ZA201702985B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
JP2020504105A (ja) * 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用
CA3056248A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
TW202144419A (zh) 2020-03-24 2021-12-01 美商建南德克公司 Ｔｉｅ２結合劑及其使用方法
TW202228790A (zh) 2020-10-15 2022-08-01 美商建南德克公司 用於長效經眼遞送之非共價蛋白質－玻尿酸結合物
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
WO2024088921A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (es) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
BR0309844A (pt) 2002-05-07 2005-02-15 Control Delivery Sys Inc Processos para formação de um dispositivo para a distribuição de droga
AU2003290682A1 (en) * 2002-11-15 2004-06-15 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
KR100864549B1 (ko) 2004-08-04 2008-10-20 어플라이드 몰리큘라 에볼류션, 인코포레이티드 변이체 ｆｃ 영역
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
KR20080090484A (ko) * 2005-12-30 2008-10-08 메르크 파텐트 게엠베하 ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체
AU2007224631A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against IL-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN101600793B (zh) 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
PL2164514T3 (pl) * 2007-05-21 2017-08-31 Alderbio Holdings Llc Przeciwciała przeciwko IL-6 i ich zastosowanie
RU2550271C2 (ru) 2007-09-14 2015-05-10 Санофи Пастер Байолоджикс Ко. Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
BRPI0820387A2 (pt) 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
NZ586828A (en) 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
EP2815766B1 (en) 2008-08-05 2017-07-05 Novartis AG Compositions and methods for antibodies targeting complement protein C5
PT2324930E (pt) 2008-09-12 2012-12-27 Kdf Co Ltd Aparelho para criar jorros de água
US20120005773A1 (en) 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
KR20110091777A (ko) 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
AU2010208125B2 (en) 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2012157167A (ru) 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
EP3489258A1 (en) * 2012-11-08 2019-05-29 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
DK3215530T3 (da) 2019-11-25
EA201791005A1 (ru) 2017-09-29
CA2965689A1 (en) 2016-05-12
HRP20191945T1 (hr) 2020-01-24
MX2021008663A (es) 2021-08-19
ES2756275T3 (es) 2020-04-27
CR20170231A (es) 2017-09-25
ES2756275T9 (es) 2020-10-29
MX2017005992A (es) 2017-09-15
SI3215530T1 (sl) 2020-02-28
BR112017008672A2 (pt) 2018-03-20
HUE046181T2 (hu) 2020-02-28
AU2015342882B2 (en) 2021-05-20
IL251858A0 (en) 2017-06-29
ZA201702985B (en) 2019-10-30
MY185114A (en) 2021-04-30
SG11201703574VA (en) 2017-05-30
EA035199B1 (ru) 2020-05-14
EP3215530B9 (en) 2020-09-09
CO2017005404A2 (es) 2017-10-31
PT3215530T (pt) 2019-11-21
JP2017535285A (ja) 2017-11-30
IL251858B (en) 2022-09-01
SG10202103420PA (en) 2021-05-28
US20220169719A1 (en) 2022-06-02
KR102636726B1 (ko) 2024-02-13
EP3215530A1 (en) 2017-09-13
MA51554A (fr) 2020-11-18
CN107249631A (zh) 2017-10-13
CA2965689C (en) 2022-03-22
NZ731090A (en) 2024-03-22
KR20240023450A (ko) 2024-02-21
HK1244008A1 (zh) 2018-07-27
CN107249631B (zh) 2021-11-23
PE20171107A1 (es) 2017-08-07
PL3215530T3 (pl) 2020-05-18
WO2016073890A1 (en) 2016-05-12
SA517381458B1 (ar) 2020-07-09
AU2015342882A1 (en) 2017-05-18
EP4268843A2 (en) 2023-11-01
EP3632931A1 (en) 2020-04-08
EP3215530B1 (en) 2019-08-21
JP6594438B2 (ja) 2019-10-23
EP4268843A3 (en) 2023-12-27
RS59805B1 (sr) 2020-02-28
US20190194312A1 (en) 2019-06-27
US11142571B2 (en) 2021-10-12
PH12017500809A1 (en) 2017-10-02
KR20170077196A (ko) 2017-07-05
UA122673C2 (uk) 2020-12-28

Similar Documents

Publication Publication Date Title
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
NI201700019A (es) Anticuerpos anti tigit
EA201790737A1 (ru) Комбинированная терапия
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
EA201691582A1 (ru) Новые фармацевтические препараты
TWD184926S (zh) 頭戴架
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
TWD180147S (zh) 淨水器
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
GT201700188A (es) Anticuerpos contra tau y sus usos
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
ZA201703467B (en) Methods of treating ocular conditions
EA201692395A1 (ru) Новые соединения
MA39411A (fr) Synthèse de l&#39;énantiomère de la progestérone et ses intermédiaires
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
EA201991866A1 (ru) Комбинированная терапия
TWD181311S (zh) 安全護目鏡